Severe heart failure: treatment with human embryonic stem cell-derived cardiac progenitors


Comparative studies suggest that stem cells committed to a cardiac lineage are more effective for improving heart function than those featuring an extra-cardiac phenotype.
Researchers have therefore developed a population of human embryonic stem cell (ESC)-derived cardiac progenitor cells.

Undifferentiated human ESCs ( I6 line ) were amplified and cardiac-committed by exposure to bone morphogenetic protein-2 and a fibroblast growth factor receptor inhibitor. Cells responding to these cardio-instructive cues express the cardiac transcription factor Isl-1 and the stage-specific embryonic antigen SSEA-1 which was then used to purify them by immunomagnetic sorting.

The Isl-1+ SSEA-1+ cells were then embedded into a fibrin scaffold which was surgically delivered onto the infarct area in a 68-year-old patient suffering from severe heart failure [ New York Heart Association ( NYHA ) functional Class III; left ventricular ejection fraction ( LVEF ): 26% ].

A coronary artery bypass was performed concomitantly in a non-infarcted area. The implanted cells featured a high degree of purity ( 99% were SSEA-1+ ), had lost the expression of Sox-2 and Nanog, taken as markers for pluripotency, and strongly expressed Isl-1.

The intraoperative delivery of the patch was expeditious. The post-operative course was uncomplicated either.

After 3 months, the patient is symptomatically improved ( NYHA functional Class I; LVEF: 36% ) and a new-onset contractility is echocardiographically evident in the previously akinetic cell/patch-treated, non-revascularized area.
There have been no complications such as arrhythmias, tumour formation, or immunosuppression-related adverse events.

In conclusion, this observation demonstrates the feasibility of generating a clinical-grade population of human ESC-derived cardiac progenitors and combining it within a tissue-engineered construct.
While any conclusion pertaining to efficacy would be meaningless, the patient's functional outcome yet provides an encouraging hint. Beyond this case, the platform that has been set could be useful for generating different ESC-derived lineage-specific progenies. ( Xagena )

Menasché P et al, Eur Heart J 2015; 36: 2011-2017

XagenaMedicines_2015



Indietro

Altri articoli

COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs...


Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure. Patients with...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Brukinsa ( Zanubrutinib ) capsules for...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...


Sarcoidosis is an important diagnostic consideration in patients with ventricular tachycardia of unknown origin. The clinical course of ventricular tachycardia...


Ondansetron ( Zofran ) is commonly used to treat vomiting in gastroenteritis, but has a United States FDA ( Food...